SWAV Stock Cash Flow Statements

ShockWave Medical Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

ShockWave Medical Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31

cash flows from operating activities:
net income	44,305,000	34,986,000	28,862,000	39,125,000	140,911,000	35,003,000	25,561,000	14,521,000	12,942,000	1,948,000	-425,000	-23,601,000	-15,874,000	-12,932,000	-18,118,000	-18,775,000	-14,745,000	-12,957,000	-10,608,000	-12,799,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	3,075,000	3,009,000	2,566,000	1,708,000	1,538,000	1,258,000	1,107,000	953,000	894,000	1,088,000	876,000	721,000	502,000	484,000	451,000	426,000	483,000	338,000	261,000	255,000
income from equity method investment	167,000	733,000	146,000	823,000	1,061,000	-97,000
stock-based compensation	21,811,000	18,410,000	17,046,000	15,967,000	12,643,000	11,732,000	11,005,000	9,510,000	8,208,000	7,387,000	6,523,000	5,139,000	3,242,000	2,846,000	2,391,000	1,871,000	1,310,000	1,106,000	818,000	412,000
non-cash lease expense	767,000	832,000	813,000	748,000	742,000	763,000
amortization of premium and discount on available-for-sale securities	-8,179,000	-2,434,000	-625,000	-718,000
loss on write down of fixed assets	131,000	114,000	15,000	11,000									90,000				-23,000	2,000	69,000	19,000
loss on extinguishment of debt
deferred income taxes	5,004,000	7,817,000	2,486,000	-547,000
amortization of debt issuance costs	945,000	494,000	35,000	33,000	60,000	163,000	157,000	153,000	154,000	18,000	172,000	167,000	168,000	165,000	160,000	153,000	114,000	110,000	108,000	104,000
foreign currency remeasurement	-1,540,000	1,035,000	-84,000	-689,000	-2,315,000	1,347,000
changes in operating assets and liabilities:
accounts receivable	-15,471,000	-2,501,000	-10,559,000	-13,004,000	-6,200,000	-4,636,000	-12,070,000	-10,407,000	-7,469,000	-5,011,000	-5,342,000	-7,924,000	-978,000	-4,346,000	1,446,000	-434,000	-1,826,000	-309,000	-1,303,000	-1,089,000
inventory	-10,391,000	-4,935,000	-7,926,000	-7,757,000	-5,339,000	-8,150,000	-6,132,000	-10,090,000	-4,091,000	-2,306,000	-2,368,000	-3,308,000	-718,000	-5,373,000	-7,158,000	-3,807,000	-2,728,000	-936,000	-1,277,000	-1,883,000
prepaid expenses and other current assets	2,677,000	-6,107,000	-1,883,000	1,896,000	-171,000	-841,000	-3,374,000	600,000	-144,000	-583,000	-1,248,000	-135,000	635,000	84,000	368,000	-1,588,000	302,000	-246,000	555,000	-1,396,000
other assets	-1,139,000	-290,000	-2,196,000	-861,000	-2,069,000	-744,000	-311,000	-119,000	-37,000	2,000	78,000	48,000	-145,000	-45,000	-69,000	-47,000	42,000	-6,000	24,000	-19,000
accounts payable	1,686,000	-5,565,000	-743,000	4,734,000	1,836,000	-1,051,000	-3,751,000	4,911,000	-298,000	898,000	-512,000	1,782,000	-616,000	-494,000	260,000	-542,000	388,000	171,000	344,000	369,000
accrued and other current liabilities	21,628,000	5,276,000	12,680,000	-6,661,000	7,564,000	435,000	12,993,000	-9,051,000	8,626,000	4,904,000	4,308,000	3,799,000	1,176,000	2,882,000	1,814,000	-1,855,000	4,170,000	2,321,000	857,000	991,000
lease liabilities	4,701,000	-933,000	-896,000	-846,000	-821,000	-643,000	-232,000	-68,000	774,000	-383,000	-280,000	-298,000	-270,000	-257,000	-163,000	-74,000	-261,000	-253,000	-259,000	-237,000
long-term income tax liability
net cash from operating activities	71,703,000	50,651,000	39,737,000	33,962,000	52,436,000	34,488,000	28,871,000	1,937,000	20,831,000	9,322,000	2,186,000	-17,303,000	-12,399,000	-16,430,000	-18,166,000	-24,189,000	-12,570,000	-10,604,000	-10,518,000	-14,415,000
capex	-8,121,000	-6,538,000	-8,748,000	-7,188,000	-11,081,000	-7,157,000	-3,602,000	-3,286,000	-2,823,000	-2,859,000	-2,706,000	-4,051,000	-1,674,000	-894,000	-4,297,000	-4,655,000	-1,530,000	-1,096,000	-771,000	-420,000
free cash flows	63,582,000	44,113,000	30,989,000	26,774,000	41,355,000	27,331,000	25,269,000	-1,349,000	18,008,000	6,463,000	-520,000	-21,354,000	-14,073,000	-17,324,000	-22,463,000	-28,844,000	-14,100,000	-11,700,000	-11,289,000	-14,835,000
cash flows from investing activities:
purchase of available-for-sale securities	-349,141,000	-342,591,000	-34,609,000	-21,130,000	-52,545,000	-32,619,000	-10,505,000	-42,128,000	-41,679,000	-48,323,000	-11,980,000	-15,263,000	-151,933,000	0	0	-16,020,000	-13,129,000	-23,563,000
proceeds from maturities of available-for-sale securities	115,000,000	43,250,000	54,000,000	34,500,000	28,350,000	34,500,000	19,923,000	18,000,000	21,400,000	46,400,000	41,900,000	46,400,000	0	13,000,000	34,000,000	25,000,000	31,450,000
purchase of property and equipment	-8,121,000	-6,538,000	-8,748,000	-7,188,000	-11,081,000	-7,157,000	-3,602,000	-3,286,000	-2,823,000	-2,859,000	-2,706,000	-4,051,000	-1,674,000	-894,000	-4,297,000	-4,655,000	-1,530,000	-1,096,000	-771,000	-420,000
business combination, net of cash acquired	0	0
net cash from investing activities	-242,262,000	-305,879,000	-83,768,000	6,182,000	-35,276,000	-5,276,000	5,816,000	-27,414,000	-23,102,000	-4,782,000	27,214,000	27,086,000	-153,607,000	12,106,000	29,703,000	4,325,000	16,791,000	7,641,000	-83,555,000	-420,000
cash flows from financing activities:
payments of taxes withheld on net settled vesting of restricted stock units	-2,000	-34,000	-4,000	-3,000	-17,000	0	0	-6,000	0	0	-3,223,000	-5,114,000	-558,000	-246,000
proceeds from debt financing	0	0
proceeds from convertible debt	-354,000
purchase of capped calls related to convertible debt
payment of assumed warrant liability	0	0
proceeds from stock option exercises	192,000	459,000	403,000	320,000	890,000	781,000	500,000	391,000	500,000	691,000	1,085,000	773,000	1,731,000	993,000	480,000	1,113,000	1,183,000	706,000	148,000	169,000
proceeds from issuance of common stock under employee stock purchase plan	0	3,138,000	0	3,092,000	0	2,352,000	0	2,135,000	0	1,696,000	0	1,141,000	0	953,000	0	842,000
principal payment of debt	0	-25,000,000
net cash from financing activities	-164,000	612,997,000	-95,841,000	83,409,000	9,596,000	383,000	500,000	2,520,000	500,000	2,387,000	-2,138,000	-3,200,000	1,173,000	1,284,000	83,648,000	3,930,000	96,372,000	491,000	-2,067,000	113,256,000
effect of exchange rate changes on cash and cash equivalents	1,100,000	-773,000	-322,000	792,000	1,602,000	-1,229,000
net increase in cash, cash equivalents and restricted cash	-169,623,000	356,996,000	-140,194,000	124,345,000	28,358,000	28,366,000	33,661,000	-22,957,000	-1,771,000	6,927,000	27,262,000	6,583,000	-164,833,000	-3,040,000	95,185,000	-15,934,000			-96,140,000	98,421,000
cash, cash equivalents and restricted cash at beginning of period	0	0	0	158,302,000	0	0	0	90,874,000	0	0	0	51,873,000	0	0	0	140,495,000	0	0	0	40,093,000
cash, cash equivalents and restricted cash equivalents at end of period	-169,623,000	356,996,000	-140,194,000	282,647,000	28,358,000	28,366,000	33,661,000	67,917,000	-1,771,000	6,927,000	27,262,000	58,456,000	-164,833,000	-3,040,000	95,185,000	124,561,000	100,593,000	-2,472,000	-96,140,000	138,514,000
supplemental disclosures of cash flow information:
interest paid	127,000	369,000	962,000	424,000	349,000	150,000	148,000	144,000	146,000	148,000	148,000	144,000	146,000	147,000	148,000	108,000	114,000	144,000	144,000	132,000
income tax paid	1,664,000	1,707,000	4,201,000	322,000	747,000	1,033,000	304,000	78,000	29,000	97,000	2,000	15,000	0	12,000			0	112,000	4,000	4,000
non-cash investing and financing activities:
right-of-use asset obtained in exchange for lease liability					0				16,479,000	5,358,000	0	48,000	105,000	82,000	0	39,000	6,875,000	0	0	73,000
property and equipment purchases included in accounts payable and accrued liabilities	1,072,000	-2,117,000	-1,384,000	6,162,000	-512,000	1,162,000	1,900,000	3,159,000	-587,000	-103,000	-491,000	3,104,000	2,215,000	-268,000	-3,535,000	4,036,000	-152,000	111,000
equity method investment obtained in exchange for related party contract liability									0	0	0	12,273,000
loss on debt extinguishment
purchases of capped calls related to convertible debt
proceeds from debt financing, net of issuance costs				80,000,000
proceeds from issuance of common stock in public offering, net of issuance costs paid
payment of deferred offering costs
principal payment of term loan
adjustments to reconcile net income to net cash provided (used) in operating activities:
accretion of discount on available-for-sale securities						-51,000	144,000	210,000	71,000	625,000	18,000	379,000	11,000	88,000	87,000	114,000	-1,000	-188,000
principal payments of term loan														0	0	-1,111,000
share in net income of equity method investment								47,000	421,000	342,000	0	5,523,000
amortization of right-of-use assets								767,000	773,000	393,000	386,000	405,000	378,000	371,000	365,000	369,000	205,000	243,000	247,000	249,000
transfer of fixed assets to inventory								44,000	59,000	50,000	104,000	116,000	216,000	23,000	134,000	40,000
change in fair value of warrant liability																	0	0	0	609,000
proceeds from issuance of common stock upon initial public offering, net of issuance costs paid																	0	-215,000	-2,215,000	102,977,000
proceeds from issuance of common stock in private placement																	0	0	0	10,000,000
proceeds from term loans
proceeds from warrant exercises																	0	0	0	110,000
common stock issued on conversion of convertible preferred stock																	0	0	0	152,806,000
offering cost included in account payable and accrued liabilities
common stock warrants issued on conversion of preferred stock warrants and the reclassification of the warrant liability																	0	0	0	789,000
payments of offering costs														0	0	-179,000
proceed from issuance of common stock from public offering, net of issuance cost paid														-416,000
net proceeds from term loan														0	0	3,265,000
offering costs included in accounts payable and accrued liabilities
other liabilities
proceeds from issuance of convertible preferred stock, net of issuance costs
issuance of series a-1 convertible preferred stock on net exercise of warrants
deferred offering cost included in account payable and accrued liabilities
issuance of common stock warrants in connection with debt financing
common stock issued upon net exercise of warrants																		0	0	133,000
deferred offering costs included in accounts payable and accrued liabilities																				2,215,000
issuance of common stock in public offering, net of issuance costs
net decrease in cash, cash equivalents and restricted cash
offering costs included in accrued liabilities
property and equipment purchases included in accounts payable																				93,000

We provide you with 20 years of cash flow statements for ShockWave Medical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ShockWave Medical stock. Explore the full financial landscape of ShockWave Medical stock with our expertly curated income statements.

The information provided in this report about ShockWave Medical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.